Novo Nordisk today announced plans to invest more than 17 bn Danish kroner in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark.
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity. These expansions will provide capacity for the production of Novo Nordisk’s current and future oral and injectable products. The new facilities will be automated and include state-of-the-art production technologies.
“This major investment in our manufacturing facilities in Kalundborg is an important step in building and ensuring future capacity for production of our current and future oral and injectable product portfolio. Kalundborg is currently the cornerstone in our production of API and the expansion of the manufacturing capacity is important to meeting the future demands of patients. The investment announced today emphasises our continued commitment to Denmark and Kalundborg being at the heart of our global manufacturing setup”, said Henrik Wulff, EVP, Product Supply, Quality & IT, Novo Nordisk.
The investment projects are expected to be finalised in 2027 and will create around 400 new jobs. More than 2,500 external staff will be engaged in the building phase.
Facts about Novo Nordisk manufacturing in Kalundborg
Novo Nordisk’s production facilities in Kalundborg were established in 1969. Today, the facilities cover an area of 1,200,000 m2 and employ about 3,200 people. In Kalundborg, Novo Nordisk manufactures products for the treatment of obesity and diabetes as well as several biopharmaceutical products. Since the turn of the millennium and until today, Novo Nordisk has invested more than 18 bn Danish kroner in the production facilities in Kalundborg. The investment announced today almost doubles 20 years of investments.
By Novo Nordisk, Press Release
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).